Ignite Creation Date:
2025-12-24 @ 6:55 PM
Ignite Modification Date:
2025-12-29 @ 10:39 PM
Study NCT ID:
NCT06802757
Status:
RECRUITING
Last Update Posted:
2025-06-17
First Post:
2025-01-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Posaconazole Plus Pembrolizumab and Chemotherapy vs Pembrolizumab and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Sponsor:
Shandong Cancer Hospital and Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-05-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-02-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-01-16
First Submit QC Date:
None
Study First Post Date:
2025-01-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-13
Last Update Post Date:
2025-06-17
Last Update Post Date Type:
ACTUAL